Skip to main navigation menu Skip to main content Skip to site footer

No. 1 (2022)

PSYCHOPHARMACOTHERAPY

Dynamics of Prevalence and Detection of Schizophrenia in the Republic of kazakhstan During the covid-19 Pandemic

https://doi.org/10.21265/PSYPH.2022.60.1.002

Published 2022-03-30

  • N.I. Raspopova
    • ,
  • Nikolay Negay
    • ,
  • Kuanysh Altynbekov
    • ,
  • Aigulim Abetova
    • ,
  • Karina Kaukerbekova

N.I. Raspopova
Kazakh-Russian Medical University

Nikolay Negay
World Health Organization Country Office Kazakhstan, Republic of Kazakhstan

Kuanysh Altynbekov
Republican Scientific and Practical Center of Mental Health

Aigulim Abetova
Republican Scientific and Practical Center of Mental Health

Karina Kaukerbekova
Kazakh-Russian Medical University

Abstract

Abstract: Modern literature data indicate that the quarantine measures introduced by WHO in connection with the COVID-19 pandemic, as well as the coronavirus infection itself, have an adverse effect on the mental health of both the population as a whole and those who already had mental disorders before the onset of pandemic period. In this regard, the study of the dynamics of prevalence and primary incidence of mental and behavioral disorders, in particular schizophrenia, is an urgent problem. The analysis of the dynamics of the prevalence and primary detection of schizophrenia in the population of the Republic of Kazakhstan presented in this paper over the past 5 years and in particular during the period of the start of quarantine measures (2020) showed that the primary referral of the population to psychiatric institutions of patients due to schizophrenia has significantly decreased, which is likely due to the strict quarantine measures that have taken place, which limited the movement of patients, as well as the recent unfavorable trend towards a decrease in the provision of some regions of Kazakhstan with psychiatric doctors. In order to improve the effectiveness of mental health care for patients with schizophrenia during the COVID-19 pandemic, it is recommended to increase the use of injectable prolonged forms of antipsychotics at home in order to avoid interruption in long-term anti-relapse therapy.

Keywords

schizophrenia, epidemiology, prevalence, incidence, COVID-19

PDF (Русский)

Author Biography

Nikolay Negay

Национальный консультант по психическому здоровью в Страновом офисе Всемирной организации здравоохранения в Казахстане.

Kuanysh Altynbekov

Генеральный директор РГКП на ПХВ "Республиканский научно-практический центр психического здоровья" Министерства здравоохранения Республики Казахстан

Aigulim Abetova

Руководитель отдела нучного менеджемента РГКП на ПХВ "Республиканский нацчно-практический центр психического здоровья" Министерства здравоохранения Республики Казахстан.

Karina Kaukerbekova

Слушатель резидентуры по специальности "Психиатрия, в том числе детская", Казахстанско-Российского медицинского университета

References

  1. Coronavirus disease (COVID-19) Pandemic. – Geneva: World Health Organization, March 23, 2020. – Available at: https://www.who.int/emergencies/diseases/novelcoronavirus-2019 (accessed February 12, 2022)
  2. Мосолов С.Н. Проблемы психического здоровья в условиях пандемии COVID-19 // Журнал неврологии и психиатрии имени С.С. Корсакова. – 2020. – № 120 (5). – С. 7–15. – DOI: 10.17116/jnevro20201200517
  3. Xiang Y.-T., Yang Y., Li W., Zhang L., Zhang Q., Cheung T., Ng C.H. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed // The Lancet Psychiatry. – 2020. – Vol. 7 (3). – Pp. 228–229. – DOI: 10.1016/S2215-0366(20)30046-8
  4. Rossi R., Socci V., Talevi D., Mensi S., Niolu C., Pacitti F., di Marco A., Rossi A., Siracusano A., di Lorenzo G. COVID-19 pandemic and lockdown measures impact on mental health among the general population in Italy // An N=18147 web-based survey. – 2020. – medRxiv preprint. – DOI: 10.1101/2020.04.09.20057802
  5. Schwartz B.J. New poll: COVID-19 impacting mental well-being: americans feeling anxious, especially for loved ones // APA News releases. – March 25, 2020. – Available at: https://www.psychiatry.org/newsroom/news-releases/new-poll-covid-19-impactingmental-well-being-americans-feeling-anxious-especially-for-loved-ones-older-adultsare-less-anxious (accessed February 12, 2022)
  6. Courtet P., Olié E., Debien C., Vaiva G. Keep socially (but not physically) connected and carry on: preventing suicide in the age of COVID-19 // J Clin Psychiatry. – 2020. – Vol. 81 (3). – 20com13370. – DOI: 10.4088/JCP.20com13370
  7. Goldberg J.F. Psychiatry’s niche role in the COVID-19 pandemic // J Clin Psychiatry. – 2020. – Vol. 81 (3). – 20com13363. – DOI: 10.4088/JCP.20com1336
  8. Goyal K., Chauhan P., Chhikara K., Gupta P., Singh M.P. Fear of COVID 2019: First suicidal case in India! // Asian J Psychiatr. – 2020. – Vol. 49 (101989). – DOI: 10.1016/j.ajp.2020.101989
  9. Webster R.K., Smith L.E., Woodland L., Wessely S., Greenberg N., Rubin G.J. The psychological impact of quarantine and how to reduce it: Rapid review of the evidence // Lancet. – 2020. – Vol. 395 (10227). – Pp. 912–920. – DOI: 10.1016/S0140-6736(20)30460-8
  10. Мосолов С.Н. Длительные психические нарушения после перенесенной острой коронавирусной инфекции SARS CoV-2 // Современная терапия психических расстройств. – 2021. – № 3. – С. 2–23. – DOI: 10.21265/PSYPH.2021.31.25.001
  11. Miners S., Kehoe P.G., Love S. Cognitive impact of COVID-19: Looking beyond the short term // Alzheimers Res Ther. – 2020. – Vol. 12 (1). – P. 170. – DOI: 10.1186/s13195-020-00744-w. – PMID: 33380345; PMCID: PMC7772800
  12. Петрова Н.Н. Здоровье пациентов с серьезными психическими заболеваниями в период COVID-19: фокус на шизофрении // Современная терапия психических расстройств. – 2021. – № 1. – С. 8–13. – DOI: 10.21265/PSYPH.2021.87.48.002
  13. Li S., Zhang Y. Mental healthcare for psychiatric inpatients during the COVID-19 epidemic// Gen. Psychiatr. -2020. – Vol. 33. – e100216. – DOI: 10.1136/gpsych-2020-100216
  14. Druss B.G. Addressing the COVID-19 pandemic in populations with serious mental illness // JAMA Psychiatry. – 2020. – DOI: b10.1001/jamapsychiatry.2020.0894
  15. Zhand N., Joober R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review // B J Psych Open. – 2021. – Vol. 7, no. 1. – e35. – DOI: 10.1192/bjo.2020.157
  16. Liu X., Lin H., Jiang H. et al. Clinical characteristics of hospitalised patients with schizophrenia who were suspected to have coronavirus disease (COVID-19) in Hubei Province, China // General Psychiatry. – 2020. – Vol. 33 (2). – e100222. – DOI: 10.1136/ gpsych-2020-100222
  17. Sheffield J.M., Karcher N.R., Barch D.M. Cognitive deficits in psychotic disorders: a lifespan perspective // Neuropsychol Rev. – 2018. – Vol. 28 (4). – P. 509–533
  18. Ученые назвали болезнь, при которой в пять раз чаще умирают от COVID-19 // РИА «Новости». – 7 декабря 2021 г. – Available at: https://ria.ru/20211207/shizofreniya-1762632966.html (accessed February 12, 2022).
  19. Miller В. Health disparities in patients with schizophrenia and COVID-19 // Psychiatric Times. – November 5, 2020. – Available at: https://www.psychiatrictimes.com/view/health-disparities-patients-schizophrenia-covid19 (accessed October 20, 2020).
  20. Stubbs B., Thompson T., Acaster S. et al. Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies // Pain. – 2015. – Vol. 156 (11). – Pp. 2121–2131.
  21. Nemani K., Li C., Olfson M. et al. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19 // JAMA Psychiatry. – 2021. – e204442. – DOI: 10.1001/jamapsychiatry.2020.4442
  22. Коронавирус: в Британии. Попробуют совмещать вакцины, шизофрения повышает риск смерти // Лондон. Казинформ. – 5 февраля 2021 г. – URL: https://www.coronavirus2020.kz/ru/koronavirus-v-britanii-poprobuyut-sovmeschat-vakcinyshizofreniya-povyshaet-risk-smerti_a3749550/amp (дата обращения 10.02.2022)
  23. Синицина Н. Психические заболевания повышали риск смерти от COVID-19 // Медвестник. – 29 ноября 2021 г. – URL: https://medvestnik.ru/content/news/Psihicheskiezabolevaniya-povyshali-risk-smerti-ot-COVID-19.html (дата обращения 12.01.2022).
  24. Названо расстройство, в пять раз увеличивающее риск смерти от COVID-19 // Радио «Спутник». – 8 декабря 2021. – URL: https://radiosputnik.ria.ru/20211208/koronavirus-1762823771.html (дата обращения 12 февраля 2022).
  25. Шизофрения в пять раз повысила риск смерти при Covid-19 // Здоровье. – 8 декабря 2021 г. URL: https://www.tatar-inform.ru/news/sizofreniya-v-pyat-raz-povysila-risksmerti-pri-covid-19-5846045 https://www.tatar-inform.ru/news/sizofreniya-v-pyatraz-povysila-risk-smerti-pri-covid-19-5846045 (дата обращения 12.02.2022).
  26. Basrak N., Mulcrone N., Sharifuddin S. et al. Risk of adverse outcome of COVID-19 among patients in secure psychiatric services: observational cohort study // B J Psych Open. – 2021. – Vol. 7, no. 1. – e31. – DOI: 10.1192/bjo.2020.169
  27. Kozloff N., Mulsant B.H., Stergiopoulos V., Voineskos A.N. The COVID-19 global pandemic: Implications for people with schizophrenia and related disorders // Schizophr Bull. – 2020. – Vol. 46 (4). – P. 752-757. – DOI: 10.1093/schbul/sbaa051
  28. Негай Н.А., Ауезова Э.Т., Ким И.Г. Психиатрическая помощь населению Республики Казахстан за 2016–2017 годы. Статистический сборник. – Алматы, 2018. – 100 с.
  29. Негай Н.А., Музафаров Р.Х., Ким И.Г., Тулендина Т.Д. Психиатрическая помощь населению Республики Казахстан за 2017–2018 годы. Статистический сборник. – Алматы, 2019. – 47 с.
  30. Негай Н.А., Музафаров Р.Х., Ким И.Г., Тулендина Т.Д. Психиатрическая помощь населению Республики Казахстан за 2018–2019 годы. Статистический сборник. – Алматы, 2020. – 57 с.
  31. Негай Н.А., Байпеисов Д.М., Тастанова А.К., Ким И.Г., Тулендина Т.Д. Служба охраны психического здоровья. Статистический сборник. 2019–2020 годы. – Алматы, 2021. – 92 с.
  32. Zandifar А., Badrfam R. COVID-19: Considering the prevalence of schizophrenia in the coming decades // Psychiatry Res. – 2020. – Vol. 288 (112982). – DOI: 10.1016/j.psychres.2020.112982
  33. Hu W., Su L., Qiao J., Zhu J., Zhou Y. COVID-19 outbreak increased risk of schizophrenia in aged adults. – 2020. – Available at: https://www.clinicaltmssociety.org/system/iles/2020.02.29-chinaxiv-covid-19-outbreak-increased-risk-of-schizophrenia-inagedadults.pdf (accessed November 20, 2020).
  34. Yesilkaya U.H., Balcioglu Y.H., Sahin S. Reissuing the sigma receptors for SARS-CoV-2//J Clin Neurosci. – 2020. – Vol. 80. – Pp. 72–73. – DOI: 10.1016/j.jocn.2020.08.014
  35. Seminog O.O., Goldacre M.J. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies // Thorax. – 2013. – Vol. 68. – Pp. 171–176. – DOI: 10.1136/thoraxjnl-2012-202480
  36. Crunfli F., Carregari V.С., Veras F.P. et al. SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability // medRxiv. – DOI: 10.1101/2020.10.09.2020746
  37. Henson Р., d’Mello R., Vaidyam А. et al. Anomaly detection to predict relapse risk in Schizophrenia // Translational Psychiatry. – 2021. – Vol. 11 (28). – DOI: 10.1038/s41398-020-01123-7
  38. Brooks S.K., Webster R.K., Smith L.E., Woodland L., Wessely S., Greenberg N., Rubin G.J. The psychological impact of quarantine and how to reduce it: rapid review of the evidence // Lancet. – 2020. – Vol. 395 (10227). – Pp. 912–920. – DOI: 10.1016/s0140-6736(20)30460-8
  39. Zhou X. Psychological crisis interventions in Sichuan Province during the 2019 novel coronavirus outbreak // Psychiatry Res. – 2020. – Vol. 286 (112895). – DOI: 10.1016/j.psychres.2020.112895
  40. The State Council of China. A notification to setup nationwide psychological assistance hotlines against the 2019-nCoV outbreak. – Published February 2, 2020. – Available at: http://www.gov.cn/xinwen/2020-02/ 02/ content_5473937.htm (accessed March 3, 2020
  41. Liu N., Zhang F., Wei C., Jia Y., Shang Z., Sun L., Wu L., Sun Z., Zhou Y., Wang Y., Liu W. Prevalence and predictors of PTSS during COVID-19 Outbreak in China Hardest-hit Areas: Gender differences matter // Psychiatry Res. – 2020. – Vol. 112921. – DOI: 10.1016/j.psychres.2020.112921
  42. Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency: Guidance for Industry and Healthcare Professionals // US Food & Drug Administration website. – Available at: https://www.fda.gov/media/136317/download (accessed March 15, 2020).
  43. Shinn A.K., Viron M. Perspectives on the COVID-19 Pandemic and Individuals With Serious Mental Illness // J Clin Psychiatry. – 2020. – Vol. 81 (3). – 20com13412. – DOI: 10.4088/JCP.20com13412
  44. Петрова Н.Н. Здоровье пациентов с серьезными психическими заболеваниями в период COVID-19: фокус на шизофрении // Современная терапия психических расстройств. – 2021. – № 1. – С. 8–13. – DOI: 10.21265/PSYPH.2021.87.48.002
  45. Мосолов С.Н. Актуальные задачи психиатрической службы в связи с пандемией COVID-19 // Современная терапия психических расстройств. – 2020. – № 2. – C. 26– 32. – DOI: 10.21265/PSYPH.2020.53.59536
  46. Correll C.U., Lauriello J. Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia // J Clin Psychiatry. – 2020. – Vol. 81, no. 4. – DOI: 10.4088/JCP.MS19053AH5C
  47. Huhn М., Nikolakopoulou А., Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis // Lancet. – 2019. – Vol. 394. – Pp. 939–951. – DOI: 10.1016/S0140-6736(19)31135-3
  48. Greene M., Yan T., Chang E. et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder // J Med Econ. – 2018. – Vol. 21 (2). – Pp. 127–134. – DOI: 10.1080/13696998.2017.1379412
  49. Recommendations for Mental Health Departments regarding activities and measures of contrast and containment of the SARS-COV-19 virus // J Italian Soc Psych Evidencebased Psychiatric Care. – 2020. – Vol. 6. – Pp. 148–150. – DOI: 10.36180/2421-4469-2020-24
  50. McKee K.A., Crocker C.E., Tibbo P.G. Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study // BMC Psychiatry. – 2021. – Vol. 21. – P. 633. – DOI: 10.1186/s12888-021-03646-9

Downloads

Download data is not yet available.